Novartis: raises annual targets

(CercleFinance.com) - On announcing its quarterly results, Novartis raised its annual targets for 2024, now expecting low double-digit growth in sales, and growth in core operating profit in the high teens.


The Swiss healthcare group posted Q3 core EPS of $2.06 and core operating profit of $5.14bn, up 20% at constant exchange rates, for a core operating margin that improved by 3.4 points to 40.1%.

At over $12.8bn, sales were up 10% in local currencies, driven by continued performances from Entresto (+26%), Cosentyx (+28%), Kisqali (+43%), Kesimpta (+28%), Pluvicto (+50%) and Leqvio (+119%).

We have completed major indications extensions for Kisqali in early breast cancer and Fabhalta in IgA nephropathy, and finalized our PSMAfore filing for Pluvicto in the US, management also highlighted.


Copyright (c) 2024 CercleFinance.com. All rights reserved.